trial

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

NCTId NCT02600741
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 296 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Primary completion 2018-07-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
296 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2015-07-24
Primary completion
2018-07-05
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Caregiver psycho-education and skills trainingCaregiver support available at the study sitePaliperidoneChlorpromazineDroperidolFluphenazineHaloperidolLoxapinePerphenazinePimozideProchlorperazineThiothixeneThioridazineTrifluoperazineAripiprazoleAsenapineClozapineIloperidoneOlanzapineQuetiapineRisperidoneZiprasidone

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
296
Phase
NA
Primary Completion Date
2018-07-05
Status
COMPLETED
relationships
The graph out of here
drug
Caregiver psycho-education and skills training
drug
Caregiver support available at the study site
drug
Paliperidone
drug
Chlorpromazine
drug
Droperidol
drug
Fluphenazine
drug
Haloperidol
drug
Loxapine
drug
Perphenazine
drug
Pimozide
drug
Prochlorperazine
drug
Thiothixene
drug
Thioridazine
drug
Trifluoperazine
drug
Aripiprazole
drug
Asenapine
drug
Clozapine
drug
Iloperidone
drug
Olanzapine
drug
Quetiapine
drug
Risperidone
drug
Ziprasidone
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication